

A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures

NCT06967012

Status	RECRUITING
Phase	Phase 4
Sponsor	Affiliated Hospital of Nantong University
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (5)

- Consent to participate in the clinical trial, and the trial subject and/or legal guardian has signed the informed consent form.
- Age 1-14 years, no gender restrictions.
- Compliant with the diagnostic criteria for focal seizures and focal-to-bilateral tonic-clonic seizures as outlined by the International League Against Epilepsy (ILAE) in 2017.
- Stable on one antiepileptic drug for e4 weeks, and deemed to be appropriate for the addition of zonisamide therapy by the investigator.
- e 2 episodes of generalized tonic-clonic seizures (secondary to focal epileptic seizures) per 28-day interval during the 8-week retrospective baseline period.

Exclusion (10)

- History of zonisamide treatment.
- History of allergy to sulfonamide drugs, zonisamide or any excipients.
- History of drug/alcohol abuse.
- History of suicide attempt or suicidal ideation within the past 6 months.
- Current use of antidepressants, anxiolytics, or antipsychotics.

... and 5 more (see full listing online)

Locations (1 total)

Affiliated Hospital of Nantong University, Nantong, Jiangsu, China